Eckert & Ziegler Radiopharma GmbH (EZR), a subsidiary of Eckert & Ziegler SE, has signed a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company.
Under the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials.
Y90-PentixaTher is a yttrium-90 (Y-90) radiolabeled peptide therapeutic designed to deliver targeted radiation to cancer cells that overexpress the C-X-C chemokine receptor type 4 (CXCR4) receptor. This receptor is found in malignancies such as acute myeloid leukemia, lymphoma, myeloma, and various solid tumors. Used alongside the gallium-68 (Ga-68)-based radiodiagnostic Ga68-PentixaFor, it supports a theranostic approach that allows physicians to visualize diseases before and after treatment.
As part of the deal, EZR will manufacture Y90-PentixaTher and manage the direct shipment of individual patient doses to trial sites. The agreement is limited to the clinical development phase and does not extend to commercial-scale manufacturing. Pentixapharm retains full strategic flexibility under the agreement to determine its future development and commercial supply.
